Aydin Huseynov
Stock Analyst at Ladenburg Thalmann
(0.77)
# 4,051
Out of 5,106 analysts
57
Total ratings
34%
Success rate
-24.2%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Aydin Huseynov
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Assumes: Buy | $11 | $6.21 | +77.13% | 1 | Mar 7, 2025 | |
| URGN UroGen Pharma | Assumes: Buy | $31 | $21.80 | +42.20% | 1 | Feb 19, 2025 | |
| MRKR Marker Therapeutics | Maintains: Buy | $11 → $19 | $1.47 | +1,192.52% | 2 | Oct 21, 2024 | |
| CRVS Corvus Pharmaceuticals | Maintains: Buy | $12 → $21 | $8.37 | +150.90% | 3 | Sep 16, 2024 | |
| CMPX Compass Therapeutics | Upgrades: Buy | $5 | $5.16 | -3.10% | 2 | Sep 16, 2024 | |
| ACRV Acrivon Therapeutics | Upgrades: Buy | $16 | $2.53 | +532.41% | 3 | Sep 16, 2024 | |
| CLDI Calidi Biotherapeutics | Initiates: Buy | $120 | $1.46 | +8,119.18% | 1 | Jun 27, 2024 | |
| CAPR Capricor Therapeutics | Maintains: Buy | $24 → $25 | $26.02 | -3.92% | 2 | May 14, 2024 | |
| SPRB Spruce Biosciences | Downgrades: Neutral | n/a | $83.40 | - | 3 | Mar 14, 2024 | |
| BDRX Biodexa Pharmaceuticals | Initiates: Buy | $2,000 | $4.75 | +42,005.26% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $7 | $1.23 | +469.11% | 1 | Dec 27, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $4.02 | +148.76% | 1 | Oct 10, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $60 | $15.13 | +296.56% | 1 | Sep 22, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 → $6 | $1.69 | +255.03% | 2 | Aug 14, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $10 | $3.29 | +203.95% | 3 | Jun 5, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $375 → $240 | $1.94 | +12,271.13% | 2 | May 16, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $104 → $182 | $3.11 | +5,752.09% | 2 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Speculative Buy | $180 → $80 | $0.27 | +29,529.63% | 1 | Apr 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $11.31 | - | 4 | Nov 4, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $1.14 | - | 2 | Aug 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $2.29 | +162.01% | 1 | Jul 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $21 | $7.59 | +176.68% | 1 | Jul 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10,500 | $10.30 | +101,841.75% | 1 | May 6, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $37 | $4.13 | +795.88% | 1 | May 2, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $300 | $54.70 | +448.45% | 3 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | n/a | $741.29 | - | 6 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $89 | $95.41 | -6.72% | 2 | Jul 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | n/a | $152.80 | - | 1 | Sep 30, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Speculative Buy | $15,000 | $0.78 | +1,922,976.92% | 1 | Jun 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $336 | $2.06 | +16,210.68% | 1 | May 21, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $18 | $4.39 | +310.02% | 1 | Mar 19, 2020 |
Ardelyx
Mar 7, 2025
Assumes: Buy
Price Target: $11
Current: $6.21
Upside: +77.13%
UroGen Pharma
Feb 19, 2025
Assumes: Buy
Price Target: $31
Current: $21.80
Upside: +42.20%
Marker Therapeutics
Oct 21, 2024
Maintains: Buy
Price Target: $11 → $19
Current: $1.47
Upside: +1,192.52%
Corvus Pharmaceuticals
Sep 16, 2024
Maintains: Buy
Price Target: $12 → $21
Current: $8.37
Upside: +150.90%
Compass Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $5
Current: $5.16
Upside: -3.10%
Acrivon Therapeutics
Sep 16, 2024
Upgrades: Buy
Price Target: $16
Current: $2.53
Upside: +532.41%
Calidi Biotherapeutics
Jun 27, 2024
Initiates: Buy
Price Target: $120
Current: $1.46
Upside: +8,119.18%
Capricor Therapeutics
May 14, 2024
Maintains: Buy
Price Target: $24 → $25
Current: $26.02
Upside: -3.92%
Spruce Biosciences
Mar 14, 2024
Downgrades: Neutral
Price Target: n/a
Current: $83.40
Upside: -
Biodexa Pharmaceuticals
Feb 8, 2024
Initiates: Buy
Price Target: $2,000
Current: $4.75
Upside: +42,005.26%
Dec 27, 2023
Initiates: Buy
Price Target: $7
Current: $1.23
Upside: +469.11%
Oct 10, 2023
Initiates: Buy
Price Target: $10
Current: $4.02
Upside: +148.76%
Sep 22, 2023
Initiates: Buy
Price Target: $60
Current: $15.13
Upside: +296.56%
Aug 14, 2023
Maintains: Buy
Price Target: $10 → $6
Current: $1.69
Upside: +255.03%
Jun 5, 2023
Maintains: Buy
Price Target: $20 → $10
Current: $3.29
Upside: +203.95%
May 16, 2023
Maintains: Buy
Price Target: $375 → $240
Current: $1.94
Upside: +12,271.13%
Apr 28, 2023
Maintains: Buy
Price Target: $104 → $182
Current: $3.11
Upside: +5,752.09%
Apr 4, 2023
Maintains: Speculative Buy
Price Target: $180 → $80
Current: $0.27
Upside: +29,529.63%
Nov 4, 2022
Downgrades: Neutral
Price Target: n/a
Current: $11.31
Upside: -
Aug 23, 2022
Downgrades: Neutral
Price Target: n/a
Current: $1.14
Upside: -
Jul 27, 2022
Initiates: Buy
Price Target: $6
Current: $2.29
Upside: +162.01%
Jul 13, 2022
Initiates: Buy
Price Target: $21
Current: $7.59
Upside: +176.68%
May 6, 2022
Initiates: Buy
Price Target: $10,500
Current: $10.30
Upside: +101,841.75%
May 2, 2022
Initiates: Buy
Price Target: $37
Current: $4.13
Upside: +795.88%
Nov 8, 2021
Upgrades: Buy
Price Target: $300
Current: $54.70
Upside: +448.45%
Nov 5, 2021
Downgrades: Hold
Price Target: n/a
Current: $741.29
Upside: -
Jul 20, 2021
Upgrades: Buy
Price Target: $89
Current: $95.41
Upside: -6.72%
Sep 30, 2020
Initiates: Hold
Price Target: n/a
Current: $152.80
Upside: -
Jun 16, 2020
Initiates: Speculative Buy
Price Target: $15,000
Current: $0.78
Upside: +1,922,976.92%
May 21, 2020
Initiates: Buy
Price Target: $336
Current: $2.06
Upside: +16,210.68%
Mar 19, 2020
Initiates: Buy
Price Target: $18
Current: $4.39
Upside: +310.02%